It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...
7h
Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives used a conference presentation to highlight the company’s shift toward ...
According to the Association for Accessible Medicine’s 2024 U.S. Generic and Biosimilar Medicines Savings Report, the use of Food and Drug Administration-approved generic and biosimilar medicines ...
The Association for Accessible Medicines and its Biosimilars Council have released an analysis undertaken by the IQVIA Institute for Human Data Science on behalf of AAM assessing the impact of patent ...
Both Alvotech ALVO and Teva Pharmaceuticals TEVA operate in the biosimilar space, but their business models differ significantly. ALVO has built its revenue model around partnerships, relying on ...
Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include novel drugs that offer new treatment options, as well as first generics and ...
The U.S. health-care system is at a crossroads. Generic drugs and biosimilars have the potential to reduce costs and improve access to life-saving treatments, but outdated policies and entrenched ...
In 2024, the use of generic and biosimilar medicines saved $467 billion for the United States health-care system and the patients who use it, according to a recent report by the Association for ...
The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
The Trump administration’s latest effort to lower drug costs is expanding to biosimilars, medications that are highly similar to biologic drugs made with or isolated from living organisms such as ...
CivicaScript, a nonprofit generic drug company, has launched insulin glargine-yfgn and ustekinumab-aauz, expanding its national portfolio of low-cost treatments. The insulin product, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback